ERS Research Seminar

Time to move forward: Challenges and Research Opportunities for Lung Cancer Screening and Early Detection in Europe

11 – 12 February 2021
Berlin, Germany

Thursday, 11 February 2021

08.30 – 08.45 Registration

08.45 – 09.00 Introduction

Session 1: Update on lung cancer screening: did we make any progress?
09.00 – 09.20 Two years after NELSON: are the data mature yet?
09.20 – 09.40 Presentation of ESTI initiative (Lung Cancer Screening Certification Project)
09.40 – 10.00 Discussion

10.00 – 10.30 Coffee break

10.30 – 11.30 Break-out session I
1 per country/region: What is currently ongoing in Europe?
• Screening initiatives after the ERS research seminar 2018: an update
• How will smoking cessation be integrated into lung cancer screening in your lung cancer screening program?
11.30 – 12.00 Report to the plenary session and discussion

12.00 – 13.00 Lunch break

Session 2: The time to implement is now
13.00 – 13.20 Making research findings more powerful for clinical use
13.20 – 13.40 Psychosocial consequences: life before and after a positive screening result
13.40 – 14.00 Targeting the hard to reach: will research on the Achilles heel of lung cancer screening defy its success?
14.00 – 14.30 Discussion

14.30 – 16.30 Break out session 2: presentation of research projects in Europe
• Group 1: Ct-scan screening implementation research
• Group 2: Non-imaging early detection research
• Group 3: ERS-task force on handling of screen detected nodules

16.30 – 17.00 Coffee break
Session 3: The world does not stand still: evolution in imaging and treatment
17.00 – 17.20  Is ultra-low-dose ready for practice?
17.20 – 17.40  Research opportunities in nodule handling: robotic surgery and beyond
17.40 – 18.00  Research opportunities in nodule handling: stereotactic ablation and beyond
18.00 – 18.30  Discussion

Friday, 12 February 2021

Session 4: Early detection biomarkers: ready for implementation in screening?
09.00 – 09.20  Biomarker performance and pathways to clinical utility
09.20 – 09.40  Genomic screening: myths, promises and achievements
09.40 – 10.00  VOC’s for lung cancer screening: where are we now?
10.00 – 10.30  Discussion

10.30 – 11.00  Coffee break

11.00 – 12.00 Report from break out session II
   • Group 1 + discussion  20’
   • Group 2 + discussion  20’
   • Group 3 + discussion  20’

Session 5: Taking research forward in the ERS
12.00 – 12.20  What is the optimal design for trials incorporating biomarkers and CT-scan screening
12.20 – 12.40  Agenda for an ERS clinical research collaboration
12.40 – 13.00  Remarks, wrap up and action points

13.00 – 14.00  Lunch

Meeting of the Task Force writing committee